{"id":"https://openalex.org/W4392369578","doi":"https://doi.org/10.1158/1538-7445.ovarian23-a076","title":"Abstract A076: T-cell exhaustion is an independent predictive biomarker of clinical outcome in high grade serous ovarian cancer regardless of homologous recombination deficiency status","display_name":"Abstract A076: T-cell exhaustion is an independent predictive biomarker of clinical outcome in high grade serous ovarian cancer regardless of homologous recombination deficiency status","alternate_titles":[],"publication_year":2024,"publication_date":"2024-03-04","ids":{"openalex":"https://openalex.org/W4392369578","doi":"https://doi.org/10.1158/1538-7445.ovarian23-a076"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.ovarian23-a076","doi":"https://doi.org/10.1158/1538-7445.ovarian23-a076","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.ovarian23-a076","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4392369578"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034316858","display_name":"Anna Salvioni","orcid":"https://orcid.org/0000-0001-5473-3785","observed_orcids":["https://orcid.org/0000-0001-5473-3785"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Anna Salvioni","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038882346","display_name":"Mathilde Del","orcid":"https://orcid.org/0000-0003-2199-6188","observed_orcids":["https://orcid.org/0000-0003-2199-6188"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Mathilde Del","raw_affiliation_strings":["2University Cancer Institute of Toulouse-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University Cancer Institute of Toulouse-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074965371","display_name":"Marie Michelas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marie Michelas","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5094046840","display_name":"Pierre Vuattoux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Pierre Vuattoux","raw_affiliation_strings":["2University Cancer Institute of Toulouse-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University Cancer Institute of Toulouse-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068593388","display_name":"Clara\u2010Maria Scarlata","orcid":"https://orcid.org/0000-0003-3429-2825","observed_orcids":["https://orcid.org/0000-0003-3429-2825"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Clara-Maria Scarlata","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055097445","display_name":"Carlos Mart\u00ednez-G\u00f3mez","orcid":"https://orcid.org/0000-0002-9652-7880","observed_orcids":["https://orcid.org/0000-0002-9652-7880"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Carlos Martinez-Gomez","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007570940","display_name":"Nathalie Van Acker","orcid":"https://orcid.org/0000-0003-0420-5081","observed_orcids":["https://orcid.org/0000-0003-0420-5081"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nathalie Van Acker","raw_affiliation_strings":["2University Cancer Institute of Toulouse-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University Cancer Institute of Toulouse-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003578489","display_name":"Fran\u00e7ois-Xavier Fr\u00e9nois","orcid":"https://orcid.org/0000-0002-8433-7764","observed_orcids":["https://orcid.org/0000-0002-8433-7764"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fran\u00e7ois-Xavier Frenois","raw_affiliation_strings":["2University Cancer Institute of Toulouse-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University Cancer Institute of Toulouse-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016581363","display_name":"Guillaume Bataillon","orcid":"https://orcid.org/0000-0003-2013-1668","observed_orcids":["https://orcid.org/0000-0003-2013-1668"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Guillaume Bataillon","raw_affiliation_strings":["2University Cancer Institute of Toulouse-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University Cancer Institute of Toulouse-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028020706","display_name":"Jean\u2010Pierre Delord","orcid":"https://orcid.org/0000-0001-7305-5561","observed_orcids":["https://orcid.org/0000-0001-7305-5561"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Pierre Delord","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045327972","display_name":"Alejandra Mart\u00ednez","orcid":"https://orcid.org/0000-0002-7633-3536","observed_orcids":["https://orcid.org/0000-0002-7633-3536"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Alejandra Martinez","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079620095","display_name":"Maha Ayyoub","orcid":"https://orcid.org/0000-0003-2022-0898","observed_orcids":["https://orcid.org/0000-0003-2022-0898"]},"institutions":[{"id":"https://openalex.org/I4210087620","display_name":"Centre de Recherches en Canc\u00e9rologie de Toulouse","ror":"https://ror.org/003412r28","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210087620","https://openalex.org/I4405258862"]},{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Maha Ayyoub","raw_affiliation_strings":["1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France,","institution_ids":["https://openalex.org/I4210087620","https://openalex.org/I4210098740"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"5_Supplement_2","first_page":"A076","last_page":"A076"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5390999913215637,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5390999913215637,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.4115999937057495,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.00559999980032444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/high-grade-serous-ovarian-carcinoma","display_name":"high-grade serous ovarian cancer","score":0.8949999809265137},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.9810000061988831},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8320000171661377},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.9610000252723694},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.7739999890327454},{"id":"https://openalex.org/keywords/tim-3","display_name":"TIM-3","score":0.996999979019165},{"id":"https://openalex.org/keywords/cd39","display_name":"CD39","score":0.9800000190734863},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.8309999704360962},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.8859999775886536},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.781000018119812},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.9850000143051147},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.8939999938011169},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7210000157356262},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.718999981880188},{"id":"https://openalex.org/keywords/clinical-outcomes","display_name":"clinical outcomes","score":0.6129999756813049},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.6309999823570251},{"id":"https://openalex.org/keywords/multiplex-immunofluorescence","display_name":"multiplex immunofluorescence","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6709582805633545},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6372135877609253},{"id":"https://openalex.org/C150173356","wikidata":"https://www.wikidata.org/wiki/Q6144101","display_name":"Serous fluid","level":2,"score":0.5907480716705322},{"id":"https://openalex.org/C102744134","wikidata":"https://www.wikidata.org/wiki/Q22280388","display_name":"Homologous recombination","level":3,"score":0.5766483545303345},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5664167404174805},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5441521406173706},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5261221528053284},{"id":"https://openalex.org/C2993684365","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Serous ovarian cancer","level":4,"score":0.5163244605064392},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.433951735496521},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24866265058517456},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.18334588408470154},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.08031067252159119}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1538-7445.ovarian23-a076","doi":"https://doi.org/10.1158/1538-7445.ovarian23-a076","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.ovarian23-a076","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmh:oai:HAL:hal-04998407v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-04998407","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"AACR Special Conference on Ovarian Cancer 2023, Oct 2023, Boston, United States. pp.A076-A076, &#x27E8;10.1158/1538-7445.OVARIAN23-A076&#x27E9;","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4392632673","https://openalex.org/W4407650919","https://openalex.org/W4407651568","https://openalex.org/W7152536530","https://openalex.org/W7223055235","https://openalex.org/W3030855383","https://openalex.org/W4282929836","https://openalex.org/W7202381924","https://openalex.org/W2915964082","https://openalex.org/W4281693032"],"abstract_inverted_index":{"Abstract":[0],"Epithelial":[1],"ovarian":[2,28,308,489],"cancer":[3,490],"is":[4,21,60,477],"the":[5,22,48,64,82,128,222,231,280,287,318,341,357,396,422,427,435,441,501],"most":[6,23],"lethal":[7],"gynecologic":[8],"malignancy,":[9],"with":[10,52,134,296,353],"5-year":[11],"survival":[12,372],"rates":[13,87],"of":[14,26,32,50,67,110,119,149,176,193,221,239,255,266,289,301,370,376,387,399,416,437,443,482,492,500],"46%.":[15],"High":[16],"grade":[17,487],"serous":[18,488],"carcinoma":[19],"(HGSC)":[20],"frequent":[24],"subtype":[25],"epithelial":[27,102,135],"cancer.":[29,309],"Approximately":[30],"50%":[31],"cases":[33],"are":[34],"homologous":[35,248,358,493],"recombination":[36,249,359,494],"deficient":[37],"(HRD).":[38],"Whereas":[39],"maintenance":[40],"treatment":[41],"by":[42,183,215,225,426],"PARP":[43],"inhibitors":[44],"has":[45],"significantly":[46,284],"improved":[47,75],"prognosis":[49],"patients":[51,133,152],"HRD":[53,168,246,274,331,334,406],"tumors,":[54,335],"clinical":[55,76,211,483],"outcome":[56,77,212,484],"in":[57,69,94,127,132,146,166,230,273,307,330,344,356,389,431,485],"this":[58],"malignancy":[59],"still":[61],"poor.":[62],"Despite":[63],"immunogenic":[65],"nature":[66],"HGSC,":[68,105],"which":[70,167,278,294],"T-cell":[71,203,223,403,410,475],"infiltration":[72,182],"correlates":[73],"to":[74,88,130,141,164,180,198,286,351,366,445],"following":[78],"surgery":[79],"and":[80,107,112,185,189,201,210,217,247,258,303,322,379,405,408,433],"chemotherapy,":[81],"disease":[83,417],"exhibits":[84],"low":[85],"response":[86,129,430,444],"immune":[89,319,429],"checkpoint":[90],"blockade":[91],"(ICB)":[92],"monotherapy":[93],"advanced":[95],"line":[96],"settings.":[97],"We":[98,172],"have":[99],"previously":[100],"identified":[101],"malignancies":[103],"including":[104],"CD4":[106,184,200,242,259,314,378],"CD8":[108,186,202,240,257,270,380],"populations":[109,123],"tumor-infiltrating":[111,143],"antigen-specific":[113],"T":[114,144,187,243,260,271,290,305,315,381],"cells":[115,145,188,244,261,272,292,306,382],"that":[116],"display":[117],"features":[118],"terminal":[120],"exhaustion.":[121,204],"These":[122],"were":[124,328],"key":[125],"players":[126],"anti-PD-1":[131],"tumors.":[136,252,275,332],"Here,":[137],"we":[138,159],"set":[139],"out":[140,384],"characterize":[142],"a":[147,400],"cohort":[148],"80":[150],"HGSC":[151,432],"treated":[153],"at":[154],"our":[155],"institution":[156],"from":[157],"whom":[158],"collected":[160],"tumor":[161,178,235],"samples":[162,179],"prior":[163],"therapy":[165],"status":[169,407,496],"was":[170,213,283,338],"assessed.":[171],"used":[173],"multiplex":[174],"immunofluorescence":[175,226],"FFPE":[177],"assess":[181,199],"multiparametric":[190],"flow":[191],"cytometry":[192],"frozen":[194],"viable":[195],"cell":[196],"suspensions":[197],"The":[205,374],"link":[206,401],"between":[207,245,340,402],"biological":[208],"parameters":[209,365],"assessed":[214],"univariable":[216],"multivariable":[218,390],"analyses.":[219,391],"Assessment":[220],"infiltrate":[224],"showed":[227,262,363],"no":[228,336],"difference":[229,337],"absolute":[232],"numbers,":[233],"per":[234],"or":[236,241],"stroma":[237],"mm2,":[238],"proficient":[250],"(HRP)":[251],"Instead,":[253],"analysis":[254],"exhausted":[256,268,313,377],"an":[263,413,478],"increased":[264],"frequency":[265],"terminally":[267,312],"PD-1HighTIM-3+":[269],"This":[276],"population,":[277],"expresses":[279],"ectonucleotidase":[281],"CD39,":[282,327],"correlated":[285],"presence":[288],"regulatory":[291,304],"(Treg),":[293],"agreed":[295],"previous":[297],"studies":[298],"showing":[299],"comigration":[300],"effector":[302],"In":[310],"addition,":[311],"cells,":[316],"expressing":[317],"checkpoints":[320],"PD-1":[321],"TIM-3":[323],"as":[324,326,385,412],"well":[325],"enriched":[329],"Among":[333],"observed":[339],"exhaustion":[342,364,404,411,476],"profile":[343],"tumors":[345],"presenting":[346],"deleterious":[347],"BRCA1/2":[348],"mutations":[349,355],"compared":[350],"those":[352],"other":[354],"pathway.":[360],"Univariable":[361],"analyses":[362],"be":[367],"significant":[368],"predictors":[369,386],"progression-free":[371],"(PFS).":[373],"frequencies":[375],"stood":[383],"PFS":[388],"Altogether,":[392],"these":[393],"results":[394],"provide":[395],"first":[397],"evidence":[398],"reveal":[409],"independent":[414,479],"predictor":[415],"outcome.":[418],"They":[419],"also":[420],"underline":[421],"major":[423],"role":[424],"played":[425],"antitumor":[428],"warrant":[434],"development":[436],"combination":[438],"immunotherapies":[439],"despite":[440],"lack":[442],"ICB":[446],"monotherapy.":[447],"Citation":[448],"Format:":[449],"Anna":[450],"Salvioni,":[451],"Mathilde":[452],"Del,":[453],"Marie":[454],"Michelas,":[455],"Pierre":[456],"Vuattoux,":[457],"Clara-Maria":[458],"Scarlata,":[459],"Carlos":[460],"Martinez-Gomez,":[461],"Nathalie":[462],"Van":[463],"Acker,":[464],"Fran\u00e7ois-Xavier":[465],"Frenois,":[466],"Guillaume":[467],"Bataillon,":[468],"Jean-Pierre":[469],"Delord,":[470],"Alejandra":[471],"Martinez,":[472],"Maha":[473],"Ayyoub.":[474],"predictive":[480],"biomarker":[481],"high":[486],"regardless":[491],"deficiency":[495],"[abstract].":[497],"In:":[498],"Proceedings":[499],"AACR":[502],"Special":[503],"Conference":[504],"on":[505],"Ovarian":[506],"Cancer;":[507],"2023":[508],"Oct":[509],"5-7;":[510],"Boston,":[511],"Massachusetts.":[512],"Philadelphia":[513],"(PA):":[514],"AACR;":[515],"Cancer":[516],"Res":[517],"2024;84(5":[518],"Suppl_2):Abstract":[519],"nr":[520],"A076.":[521]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4392369578","counts_by_year":[],"updated_date":"2026-10-25T09:29:13.331239","created_date":"2024-03-05T00:00:00"}
